Harvard Bioscience (HBIO) Operating Expenses (2010 - 2026)

Harvard Bioscience (HBIO) has 17 years of Operating Expenses data on file, last reported at $13.4 million in Q1 2026.

• Operating Expenses for Q1 2026 came in at $13.4 million, down 78.31% year-over-year; the trailing twelve-month figure through Mar 2026 was $50.1 million (down 52.68% YoY), and the FY2025 annual result was $98.5 million, up 61.52% from the prior year.
• Operating Expenses improved to $13.4 million in Q1 2026 per HBIO's latest filing, from $12.5 million in the prior quarter.
• Over five years, Operating Expenses peaked at $61.9 million in Q1 2025 and troughed at $11.8 million in Q3 2025.
• A 5-year average of $17.9 million and a median of $15.7 million in 2023 frame the typical range for Operating Expenses.
• The sharpest annual moves came in 2025 and 2026: Operating Expenses surged 262.75% in 2025, then plunged 78.31% in 2026.
• A 5-year view of Operating Expenses shows it stood at $16.3 million in 2022, then decreased by 1.52% to $16.0 million in 2023, then slipped by 12.73% to $14.0 million in 2024, then fell by 10.99% to $12.5 million in 2025, then advanced by 7.67% to $13.4 million in 2026.
• Business Quant data shows HBIO's Operating Expenses at $13.4 million in Q1 2026, $12.5 million in Q4 2025, and $11.8 million in Q3 2025.